At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
News|Articles|September 17, 2026
End-to-End Commercialization Guide
Author(s)Envision Pharma
Two Labs and Riparian, both part of Envision Pharma Group, work alongside specialty pharma manufacturers at nearly every stage of commercialization — government pricing and compliance, patient support programs, specialty pharmacy selection, trade and distribution, and post-launch optimization. Each chapter of this guide was written by the experts who lead that work, drawing on real conversations with manufacturers navigating these decisions.
Advertisement
What's Inside
- How pricing pressure, the IRA, and drug price transparency laws are reshaping commercial strategy
- Why patient support has become a commercial imperative, not an operational function
- How to select and implement a specialty pharmacy partner before launch
- Where post-launch optimization breaks down — and how to connect strategy to performance
- Insights from Two Labs and Riparian experts across every stage of commercialization
- PLUS: A Pre-Launch Readiness Assessment: Click here to take it
Advertisement
Related to this article
Octapharma USA's Kerem Tokel explains how tariffs and DSCSA are affecting how stolen pharma loads are resold, and why partner SOPs matter.
At LogiPharma USA 2026, Mark Talens explains where pharma gains the most from shared distribution visibility.
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Freehand CEO Nitin Jayakrishnan explains why pharma manufacturers are trading long-term plans for operating models built to sense and pivot.
PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how onshoring, geopolitical risk and a shifting product mix are driving supply chain automation.
At LogiPharma USA 2026, quality leaders explained why connected data, risk-based prioritization, and human accountability must come before AI in supply chain compliance.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Why Securing Pharma Freight Starts With Broker and Carrier SOPs
2
LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk
3
Supply Chain Visibility Needs Context Before AI, Says PAXAFE’s Mark Talens
4
Pharma Pulse: PhRMA Sues to Block GLOBE Model and Bayer's $2.2B Ohio Site
5